Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has received an average rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $20.00.

A number of research firms have recently weighed in on NBTX. Guggenheim upped their price target on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research note on Thursday, January 22nd. TD Cowen initiated coverage on Nanobiotix in a research report on Friday, February 6th. They issued a “buy” rating on the stock. Finally, Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th.

Hedge Funds Weigh In On Nanobiotix

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Millennium Management LLC acquired a new stake in Nanobiotix in the fourth quarter valued at approximately $390,000. Marshall Wace LLP acquired a new position in shares of Nanobiotix during the 4th quarter worth $220,000. Optiver Holding B.V. bought a new position in shares of Nanobiotix during the 3rd quarter valued at $101,000. Finally, Royal Bank of Canada raised its holdings in shares of Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Trading Up 18.1%

NBTX stock opened at $40.13 on Thursday. The company has a 50 day moving average of $24.25 and a two-hundred day moving average of $20.56. Nanobiotix has a 12-month low of $2.95 and a 12-month high of $41.89.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.